Abstract
HLA evolutionary divergence (HED), a continuous metric quantifying the differences between each amino acid of two homologous HLA alleles, reflects the importance of the immunopeptidome presented to T lymphocytes. It has been associated with rejection after liver transplantation. This retrospective cohort study aimed to analyze the potential effect of donor or recipient HED on liver transplant rejection in a new series of patients transplanted during childhood and followed in adulthood. The study included 120 children who had been transplanted between 1991 and 2010 and were followed by routine biopsies and histological evaluations with a median of 14.1 years post-LT. Liver biopsies were performed routinely 1, 5, 10 and 20 years after transplantation and in the event of liver dysfunction. HED was calculated using the physicochemical Grantham distance for donor and recipient class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) alleles. The influence of HED on rejection was analyzed using IPW and target trial emulation using the g method. Based on the IPW score, donor HED class I was correlated with the occurrence of late (>90 days) rejection (HR, 1.19, 95% CI: 1.01-1.40) independently of HLA mismatches, donor age and initial induction. This emulated target trial confirmed that donor HED class I has a causal effect on liver graft rejection and this relationship was observed long-term.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the local Ethics Committee and was performed in accordance with the principles of the Declaration of Helsinki.It was approved by the Scientific and Ethical Committee of Hospices Civils de Lyon, France.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial support: There was no funding source for this study.
Primary Funding Source: None
Abbreviations
- CBGPS
- covariate balancing generalized propensity scores
- CNI
- Calcineurin-Inhibitors
- CSA
- Cyclosporine
- DSA
- Donor Specific Antibody
- HED
- HLA Evolutionary Divergence
- HLA
- Human Leucocyte Antigen
- IPW
- Inverse Probability Weighting
- MMF
- Mycophenolate Mofetil
- TAC
- Tacrolimus
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.